11/1/2018 7:19:19 AM
Teva Pharmaceutical Industries Limited (TEVA) Has Raised Its FY18 Revenue Estimate To $18.6 - $19.0 Bln From $18.5 - $19.0 Bln
11/1/2018 7:18:40 AM
Teva Pharmaceutical Industries Limited (TEVA) Has Raised Its FY18 EPS Estimate To 2.80 - 2.95 From 2.55 - 2.80
11/1/2018 7:01:29 AM
Teva Q3 GAAP Loss Per Share Of $0.27; Non-GAAP EPS $0.68
10/11/2018 5:01:13 AM
Teva Draws On Patient Experience To Empower Those Living With Chronic Conditions
10/10/2018 11:02:50 AM
Teva Presents 25-year Safety Data From Longest Continuous Trial Of COPAXONE For Treatment Of RMS
10/9/2018 9:02:58 AM
Celmatix Enters Partnership To Bring The Fertilome Genetic Test To Israel
10/8/2018 7:02:54 AM
Teva To Present New Data At 34th European Committee For Treatment And Research In Multiple Sclerosis Congress In Berlin
9/18/2018 7:02:07 AM
Teva Reports Early Results Of Debt Tender Offer And Election Of Early Settlement
9/6/2018 1:22:58 AM
Teva Announces Series Of Partnerships And Initiatives In Europe
9/5/2018 9:48:25 AM
Teva Appoints John Nason President, TAPI And Biologics Operations